Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease

Li Ting Ho, Lian Yu Lin, Yao Hsu Yang, Cho Kai Wu, Jyh Ming Jimmy Juang, Yi Chih Wang, Chia Ti Tsai, Ling Ping Lai, Juey Jen Hwang, Fu Tien Chiang, Jiunn Lee Lin, Pau Chung Chen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives The objective is to assess the effectiveness of statin use to prevent atrial fibrillation (AF) in dialysis patients. Methods We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI), which encompasses almost 100% of the patients receiving dialysis started from 1997 to 2008 in Taiwan. All dialysis patients aged 18 or older without history of cardiovascular events in 1997 and 1998 were incorporated. Finally, 113,191 dialysis patients were enrolled. We used propensity score (PS) matching method and Cox's proportional hazard regression models to estimate hazard ratios for AF events for statin users vs. nonusers. Results In statin group, the incidence of developing new AF was significantly lower than that in control group (1.1% vs. 3.8%, P < 0.001). The PS-based selection process identified 2146 patients receiving statins and 2146 who did not receive statins. The incidence of developing AF remained lower in statin group than that in control group (2.4% vs. 4.9%, P < 0.001). After PS matching, Cox's proportional hazard regression analyses showed that there was a protective effect of developing AF in a dose-responsive manner. The protective effect was more obvious in subjects with younger age, female gender, hyperlipidemia, coronary artery disease and peripheral artery disease and in subjects without taking angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Conclusion Our analyses showed that statin therapy was associated with lower risk of newly diagnosed AF in patients with dialysis.

Original languageEnglish
Pages (from-to)538-543
Number of pages6
JournalInternational Journal of Cardiology
Volume201
DOIs
Publication statusPublished - Oct 10 2015
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atrial Fibrillation
Chronic Kidney Failure
Dialysis
Propensity Score
Therapeutics
Catastrophic Illness
Control Groups
Angiotensin Receptor Antagonists
Peripheral Arterial Disease
Incidence
Hyperlipidemias
Taiwan
Proportional Hazards Models
Angiotensin-Converting Enzyme Inhibitors
Registries
Coronary Artery Disease
Regression Analysis
Databases
Health

Keywords

  • Atrial fibrillation
  • Dialysis
  • Propensity score
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease. / Ho, Li Ting; Lin, Lian Yu; Yang, Yao Hsu; Wu, Cho Kai; Juang, Jyh Ming Jimmy; Wang, Yi Chih; Tsai, Chia Ti; Lai, Ling Ping; Hwang, Juey Jen; Chiang, Fu Tien; Lin, Jiunn Lee; Chen, Pau Chung.

In: International Journal of Cardiology, Vol. 201, 10.10.2015, p. 538-543.

Research output: Contribution to journalArticle

Ho, LT, Lin, LY, Yang, YH, Wu, CK, Juang, JMJ, Wang, YC, Tsai, CT, Lai, LP, Hwang, JJ, Chiang, FT, Lin, JL & Chen, PC 2015, 'Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease', International Journal of Cardiology, vol. 201, pp. 538-543. https://doi.org/10.1016/j.ijcard.2015.01.040
Ho, Li Ting ; Lin, Lian Yu ; Yang, Yao Hsu ; Wu, Cho Kai ; Juang, Jyh Ming Jimmy ; Wang, Yi Chih ; Tsai, Chia Ti ; Lai, Ling Ping ; Hwang, Juey Jen ; Chiang, Fu Tien ; Lin, Jiunn Lee ; Chen, Pau Chung. / Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease. In: International Journal of Cardiology. 2015 ; Vol. 201. pp. 538-543.
@article{bbce0a4723d34f8cb6f18de18c0c06c3,
title = "Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease",
abstract = "Objectives The objective is to assess the effectiveness of statin use to prevent atrial fibrillation (AF) in dialysis patients. Methods We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI), which encompasses almost 100{\%} of the patients receiving dialysis started from 1997 to 2008 in Taiwan. All dialysis patients aged 18 or older without history of cardiovascular events in 1997 and 1998 were incorporated. Finally, 113,191 dialysis patients were enrolled. We used propensity score (PS) matching method and Cox's proportional hazard regression models to estimate hazard ratios for AF events for statin users vs. nonusers. Results In statin group, the incidence of developing new AF was significantly lower than that in control group (1.1{\%} vs. 3.8{\%}, P < 0.001). The PS-based selection process identified 2146 patients receiving statins and 2146 who did not receive statins. The incidence of developing AF remained lower in statin group than that in control group (2.4{\%} vs. 4.9{\%}, P < 0.001). After PS matching, Cox's proportional hazard regression analyses showed that there was a protective effect of developing AF in a dose-responsive manner. The protective effect was more obvious in subjects with younger age, female gender, hyperlipidemia, coronary artery disease and peripheral artery disease and in subjects without taking angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Conclusion Our analyses showed that statin therapy was associated with lower risk of newly diagnosed AF in patients with dialysis.",
keywords = "Atrial fibrillation, Dialysis, Propensity score, Statins, Atrial fibrillation, Dialysis, Propensity score, Statins",
author = "Ho, {Li Ting} and Lin, {Lian Yu} and Yang, {Yao Hsu} and Wu, {Cho Kai} and Juang, {Jyh Ming Jimmy} and Wang, {Yi Chih} and Tsai, {Chia Ti} and Lai, {Ling Ping} and Hwang, {Juey Jen} and Chiang, {Fu Tien} and Lin, {Jiunn Lee} and Chen, {Pau Chung}",
year = "2015",
month = "10",
day = "10",
doi = "10.1016/j.ijcard.2015.01.040",
language = "English",
volume = "201",
pages = "538--543",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Statin therapy lowers the risk of new-onset atrial fibrillation in patients with end-stage renal disease

AU - Ho, Li Ting

AU - Lin, Lian Yu

AU - Yang, Yao Hsu

AU - Wu, Cho Kai

AU - Juang, Jyh Ming Jimmy

AU - Wang, Yi Chih

AU - Tsai, Chia Ti

AU - Lai, Ling Ping

AU - Hwang, Juey Jen

AU - Chiang, Fu Tien

AU - Lin, Jiunn Lee

AU - Chen, Pau Chung

PY - 2015/10/10

Y1 - 2015/10/10

N2 - Objectives The objective is to assess the effectiveness of statin use to prevent atrial fibrillation (AF) in dialysis patients. Methods We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI), which encompasses almost 100% of the patients receiving dialysis started from 1997 to 2008 in Taiwan. All dialysis patients aged 18 or older without history of cardiovascular events in 1997 and 1998 were incorporated. Finally, 113,191 dialysis patients were enrolled. We used propensity score (PS) matching method and Cox's proportional hazard regression models to estimate hazard ratios for AF events for statin users vs. nonusers. Results In statin group, the incidence of developing new AF was significantly lower than that in control group (1.1% vs. 3.8%, P < 0.001). The PS-based selection process identified 2146 patients receiving statins and 2146 who did not receive statins. The incidence of developing AF remained lower in statin group than that in control group (2.4% vs. 4.9%, P < 0.001). After PS matching, Cox's proportional hazard regression analyses showed that there was a protective effect of developing AF in a dose-responsive manner. The protective effect was more obvious in subjects with younger age, female gender, hyperlipidemia, coronary artery disease and peripheral artery disease and in subjects without taking angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Conclusion Our analyses showed that statin therapy was associated with lower risk of newly diagnosed AF in patients with dialysis.

AB - Objectives The objective is to assess the effectiveness of statin use to prevent atrial fibrillation (AF) in dialysis patients. Methods We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI), which encompasses almost 100% of the patients receiving dialysis started from 1997 to 2008 in Taiwan. All dialysis patients aged 18 or older without history of cardiovascular events in 1997 and 1998 were incorporated. Finally, 113,191 dialysis patients were enrolled. We used propensity score (PS) matching method and Cox's proportional hazard regression models to estimate hazard ratios for AF events for statin users vs. nonusers. Results In statin group, the incidence of developing new AF was significantly lower than that in control group (1.1% vs. 3.8%, P < 0.001). The PS-based selection process identified 2146 patients receiving statins and 2146 who did not receive statins. The incidence of developing AF remained lower in statin group than that in control group (2.4% vs. 4.9%, P < 0.001). After PS matching, Cox's proportional hazard regression analyses showed that there was a protective effect of developing AF in a dose-responsive manner. The protective effect was more obvious in subjects with younger age, female gender, hyperlipidemia, coronary artery disease and peripheral artery disease and in subjects without taking angiotensin converting enzyme inhibitor and angiotensin receptor blocker. Conclusion Our analyses showed that statin therapy was associated with lower risk of newly diagnosed AF in patients with dialysis.

KW - Atrial fibrillation

KW - Dialysis

KW - Propensity score

KW - Statins

KW - Atrial fibrillation

KW - Dialysis

KW - Propensity score

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84943577291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943577291&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.01.040

DO - 10.1016/j.ijcard.2015.01.040

M3 - Article

C2 - 26322603

AN - SCOPUS:84943577291

VL - 201

SP - 538

EP - 543

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -